Jones David Scott 4
4 · EyePoint Pharmaceuticals, Inc. · Filed Feb 13, 2024
Insider Transaction Report
Form 4
Jones David Scott
SVP & Chief Commercial Officer
Transactions
- Exercise/Conversion
Restricted Stock Units
2024-02-09−5,000→ 5,000 totalExercise: $0.00Exp: 2032-02-09→ Common Stock (5,000 underlying) - Exercise/Conversion
Common Stock
2024-02-09+5,000→ 48,572 total - Exercise/Conversion
Common Stock
2024-02-09+4,967→ 43,572 total - Tax Payment
Common Stock
2024-02-09$28.80/sh−1,955$56,304→ 46,617 total - Tax Payment
Common Stock
2024-02-09$28.80/sh−1,701$48,989→ 44,916 total - Exercise/Conversion
Restricted Stock Units
2024-02-09−4,967→ 0 totalExercise: $0.00Exp: 2031-02-09→ Common Stock (4,967 underlying)
Footnotes (4)
- [F1]Includes 643 shares acquired on January 31, 2024 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.
- [F2]No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units
- [F3]The restricted stock units will vest in three ratable annual installments beginning February 9, 2022.
- [F4]The restricted stock units will vest in three ratable annual installments beginning February 9, 2023.